As international medical cannabis demand surges, a shift in global regulatory landscapes is creating a distinct advantage for producers with pharmaceutical-grade infrastructure. While the headline number is steady, international medical cannabis revenue reached $25.2M for the year, representing 43% growth over the prior year and crossing the threshold to represent more than 50% of total company revenue. Q4 revenue came in at $11.1M (compared to $12.0M in Q4 2024), reflecting timing and product mix differences rather than a structural decline. What separates the firm from most producers attempting to access international markets is the regulatory credential stack it has assembled. Germany's regulatory shift has driven robust patient growth, and the country now represents the largest medical cannabis market outside North America.

Source: International New York Times March 31, 2026 06:06 UTC